Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Feb;69(2):217–221. doi: 10.1038/bjc.1994.42

Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line.

S Isonishi 1, D K Hom 1, A Eastman 1, S B Howell 1
PMCID: PMC1968705  PMID: 8297717

Abstract

Sensitivity to platinum-containing drugs is believed to be a function of how much drug enters the cell, the extent of DNA adduct formation and the rate at which DNA is repaired. Activation of protein kinase C by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) was found to enhance the sensitivity of human ovarian carcinoma 2008 cells to cisplatin (DDP), carboplatin (CBDCA) and (glycolato-O,O') diammineplatinum(II) (254-S). TPA was able to enhance the sensitivity of the DDP-resistant 2008/C13*5.25 subline to each of the three drugs to the same extent as for the 2008 cells. TPA produced no significant change in the uptake of [3H]cis-dichloro(ethylenediamine)-platinum(II). ([3H]DEP) or CBDCA. It did not alter glutathione content or glutathione-S-transferase activity, and induced rather than suppressed metallothionein IIA mRNA levels. TPA did increase the formation of intrastrand guanine-guanine cross-links by a factor of 1.5 +/- 0.3 (s.d.), and reduced the fraction of intrastrand adducts removed from DNA over the subsequent 24 h by a factor of 1.3 +/- 0.2 (s.d.) (n = 4; P < 0.05), however, these effects were too small to account for the degree of TPA-induced sensitisation. These results indicate that the mechanism of TPA-induced sensitisation is not specific to any one structural form of platinum-containing drug, and that it is not readily explicable on the basis of an effect on the four major parameters currently believed to regulate DDP sensitivity.

Full text

PDF
217

Images in this article

220Figure 5
on p.220

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed S., Lee J., Kozma R., Best A., Monfries C., Lim L. A novel functional target for tumor-promoting phorbol esters and lysophosphatidic acid. The p21rac-GTPase activating protein n-chimaerin. J Biol Chem. 1993 May 25;268(15):10709–10712. [PubMed] [Google Scholar]
  2. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  3. Andrews P. A., Murphy M. P., Howell S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 1985 Dec;45(12 Pt 1):6250–6253. [PubMed] [Google Scholar]
  4. Andrews P. A., Schiefer M. A., Murphy M. P., Howell S. B. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact. 1988;65(1):51–58. doi: 10.1016/0009-2797(88)90030-0. [DOI] [PubMed] [Google Scholar]
  5. Beck D. J., Brubaker R. R. Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli. J Bacteriol. 1973 Dec;116(3):1247–1252. doi: 10.1128/jb.116.3.1247-1252.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Berenbaum M. C. What is synergy? Pharmacol Rev. 1989 Jun;41(2):93–141. [PubMed] [Google Scholar]
  7. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  8. Chuang L. F., Cooper R. H., Yau P., Bradbury E. M., Chuang R. Y. Protein kinase C phosphorylates leukemia RNA polymerase II. Biochem Biophys Res Commun. 1987 Jun 30;145(3):1376–1383. doi: 10.1016/0006-291x(87)91590-7. [DOI] [PubMed] [Google Scholar]
  9. DiSaia P. J., Sinkovics J. G., Rutledge F. N., Smith J. P. Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol. 1972 Dec 1;114(7):979–989. doi: 10.1016/0002-9378(72)90109-3. [DOI] [PubMed] [Google Scholar]
  10. Eastman A. Analysis and quantitation of the DNA damage produced in cells by the cisplatin analog cis-[3H]dichloro(ethylenediamine)platinum (II). Anal Biochem. 1991 Sep 2;197(2):311–315. doi: 10.1016/0003-2697(91)90397-c. [DOI] [PubMed] [Google Scholar]
  11. Eastman A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry. 1983 Aug 2;22(16):3927–3933. doi: 10.1021/bi00285a031. [DOI] [PubMed] [Google Scholar]
  12. Garrett S. H., Xiong X., Arizono K., Brady F. O. Phorbol ester induction of rat hepatic metallothionein in vivo and in vitro. Int J Biochem. 1992 Oct;24(10):1669–1676. doi: 10.1016/0020-711x(92)90186-5. [DOI] [PubMed] [Google Scholar]
  13. Godwin A. K., Meister A., O'Dwyer P. J., Huang C. S., Hamilton T. C., Anderson M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070–3074. doi: 10.1073/pnas.89.7.3070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gunning P., Ponte P., Okayama H., Engel J., Blau H., Kedes L. Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol Cell Biol. 1983 May;3(5):787–795. doi: 10.1128/mcb.3.5.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Isonishi S., Andrews P. A., Howell S. B. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem. 1990 Mar 5;265(7):3623–3627. [PubMed] [Google Scholar]
  16. Karin M., Richards R. I. Human metallothionein genes: molecular cloning and sequence analysis of the mRNA. Nucleic Acids Res. 1982 May 25;10(10):3165–3173. doi: 10.1093/nar/10.10.3165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Krauss S. W., Mochly-Rosen D., Koshland D. E., Jr, Linn S. Exposure of HeLa DNA polymerase alpha to protein kinase C affects its catalytic properties. J Biol Chem. 1987 Mar 15;262(8):3432–3435. [PubMed] [Google Scholar]
  18. Lee W., Mitchell P., Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell. 1987 Jun 19;49(6):741–752. doi: 10.1016/0092-8674(87)90612-x. [DOI] [PubMed] [Google Scholar]
  19. Leung T., How B. E., Manser E., Lim L. Germ cell beta-chimaerin, a new GTPase-activating protein for p21rac, is specifically expressed during the acrosomal assembly stage in rat testis. J Biol Chem. 1993 Feb 25;268(6):3813–3816. [PubMed] [Google Scholar]
  20. Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984 May;100(5):704–713. doi: 10.7326/0003-4819-100-5-704. [DOI] [PubMed] [Google Scholar]
  21. Mann S. C., Andrews P. A., Howell S. B. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol. 1990;25(4):236–240. doi: 10.1007/BF00684878. [DOI] [PubMed] [Google Scholar]
  22. Masuda H., Tanaka T., Matsuda H., Kusaba I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1990 Mar 15;50(6):1863–1866. [PubMed] [Google Scholar]
  23. Meyn R. E., Jenkins S. F., Thompson L. H. Defective removal of DNA cross-links in a repair-deficient mutant of Chinese hamster cells. Cancer Res. 1982 Aug;42(8):3106–3110. [PubMed] [Google Scholar]
  24. Plooy A. C., van Dijk M., Berends F., Lohman P. H. Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res. 1985 Sep;45(9):4178–4184. [PubMed] [Google Scholar]
  25. Rice G. C., Bump E. A., Shrieve D. C., Lee W., Kovacs M. Quantitative analysis of cellular glutathione by flow cytometry utilizing monochlorobimane: some applications to radiation and drug resistance in vitro and in vivo. Cancer Res. 1986 Dec;46(12 Pt 1):6105–6110. [PubMed] [Google Scholar]
  26. Sahyoun N., LeVine H., 3rd, McConnell R., Bronson D., Cuatrecasas P. A specific phosphoprotein phosphatase acts on histone H1 phosphorylated by protein kinase C. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6760–6764. doi: 10.1073/pnas.80.22.6760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sahyoun N., Wolf M., Besterman J., Hsieh T., Sander M., LeVine H., 3rd, Chang K. J., Cuatrecasas P. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1603–1607. doi: 10.1073/pnas.83.6.1603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Samuels D. S., Shimizu Y., Shimizu N. Protein kinase C phosphorylates DNA topoisomerase I. FEBS Lett. 1989 Dec 18;259(1):57–60. doi: 10.1016/0014-5793(89)81493-0. [DOI] [PubMed] [Google Scholar]
  29. Sheibani N., Jennerwein M. M., Eastman A. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry. 1989 Apr 4;28(7):3120–3124. doi: 10.1021/bi00433a055. [DOI] [PubMed] [Google Scholar]
  30. Shrieve D. C., Bump E. A., Rice G. C. Heterogeneity of cellular glutathione among cells derived from a murine fibrosarcoma or a human renal cell carcinoma detected by flow cytometric analysis. J Biol Chem. 1988 Oct 5;263(28):14107–14114. [PubMed] [Google Scholar]
  31. Sorenson C. M., Eastman A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res. 1988 Dec 1;48(23):6703–6707. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES